Abstract
High risk non-muscle invasive superficial bladder cancer patients have life-long risk of progression and require particular attention. Bacille Calmette-Guérin (BCG) instillation is recommended as first-choice treatment to reduce the risk of progression of high-grade bladder cancer and carcinoma in situ (CIS). We tried to evaluate the need for routine transuretheral biopsy from the previous resection site at 3 months, after BCG instillation therapy, even if post-treatment urine cytology and cystoscopy were free.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
